Antigenics, Inc. (NASDAQ:AGEN)

CAPS Rating: 3 out of 5

A biotechnology company, developing technologies and products to treat cancers and infectious diseases, based on immunological approaches.


Player Avatar zzlangerhans (99.81) Submitted: 5/6/2011 2:13:16 AM : Outperform Start Price: $5.34 AGEN Score: -44.68

0.9 has been a relatively stable floor for Agenus over the last eight months. Potential positive catalysts include presentation of data from phase II trial of Prophage G-200 in glioma and results of several phase III vaccine trials by collaborators using the QS-21 adjuvant. The absence of revenues resulting from Russian approval of Oncophage seems to be a forgotten issue.

I still believe that Agenus's immunotherapy pipeline isn't much more than a scam. On the other hand, their vaccine adjuvant seems to have attracted some fairly deep-pocketed collaborators. At this price and in a simulated situation, Agenus gets the benefit of the doubt for now.

Featured Broker Partners